Compare Nuwellis Inc (NUWE) vs Global X Uranium ETF (URA) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Nuwellis Inc vs Global X Uranium ETF — how do they compare? Nuwellis Inc trades at $0.68 (market cap $2.20M), while Global X Uranium ETF trades at $38.72 (market cap $5.48B). The key difference: Global X Uranium ETF is far larger — about 2490.9× Nuwellis Inc's market cap, and Nuwellis Inc is more actively traded (121,544 versus 5,287,170). Which is the better fit depends on your goals — on Pluang, investors hold Nuwellis Inc for 26 Days and Global X Uranium ETF for 62 Days on average.
| NUWE | URA | |
|---|---|---|
Market Cap | $2.20M | $5.48B |
Volume | 121,544 | 5,287,170 |
Sector | Health | Commodities - Metals/Agriculture |
52-Week High | $146.65 | $61.81 |
52-Week Low | $0.68 | $37.52 |
Typical Hold Time | 26 Days | 62 Days |
Enterprise Value | -$1.52M | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
NUWE trades at $0.6907, down 1.48% on the day, with a bearish technical signal from moving averages despite oversold RSI readings. The company reported revenue growth to $9M in 2026 but remains deeply unprofitable with a net income margin of -125.63%. Recent news highlights console sales growth and strategic expansions in pediatric and critical care markets.
The outlook is high-risk due to persistent losses and negative cash flow, though analyst sentiment is split with a 50% buy rating. Investment potential hinges on the company's ability to achieve profitability and scale its Aquadex platform, while risks include cash burn and competitive pressures in the medical device sector.
URA is trading at $38.58, down 3.38% today amid bearish technical signals. The ETF shows negative momentum with all 13 moving averages signaling sell. Recent news highlights nuclear energy's growth potential, including US-Saudi atomic deals and AI-driven power demand, though uranium miners face price volatility. The fund provides diversified exposure to uranium miners, utilities, and nuclear infrastructure companies.
Outlook remains cautiously optimistic given nuclear energy's structural growth drivers, but near-term pressure persists from uranium price fluctuations. Key risks include commodity volatility and regulatory uncertainty, while catalysts include government nuclear investments and AI power demand. The current technical weakness may present entry opportunities for long-term investors.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Nuwellis Inc
Nuwellis, Inc. is a medical device company focused on developing and commercializing fluid management solutions. The company's primary product is an ultrafiltration system used in hospitals to remove excess fluid from patients with fluid overload, often associated with conditions such as heart and kidney failure. Nuwellis aims to improve patient outcomes and reduce healthcare costs through its specialized, innovative therapies.
Read more on NUWE →About Global X Uranium ETF
URA provides broad exposure to the global uranium industry and nuclear energy sector. Unlike pure-play mining funds, it includes companies involved in nuclear component production and infrastructure, with top 2026 holdings such as Cameco, Oklo, and Uranium Energy Corp.
Read more on URA →
